Pharmacy, Barts Health NHS Trust, London, UK
Pharmacy, Barts Health NHS Trust, London, UK.
Eur J Hosp Pharm. 2023 Dec 27;31(1):73-75. doi: 10.1136/ejhpharm-2021-003172.
The aim of this study was to explore the nature of clinical enquiries received by UK vaccination centres during the early stages in the roll-out of the COVID-19 vaccination programme. Four centres were situated in acute hospitals and one centre was in a designated public site. Data were collected for eight consecutive weeks between January and February 2021. The hospital centres administered a total of 28 995 doses of the Pfizer BioNTech vaccine, receiving 806 enquiries (1 enquiry per 36 vaccinations, 2.7%). The public centre administered 29 167 doses of AstraZeneca vaccine, receiving 439 enquiries (1 enquiry per 66 vaccinations, 1.5%). Combined enquiry rate was 2.1%. The most common enquiries were related to allergies (44%), compatibility with other medicine (22%) and immunosuppression (16%). These were the topics of clinical guidance that were subject to regular change. Public health programmes implementing novel therapies should ensure the provision of sufficient enquiry answering capacity.
这项研究旨在探索在 COVID-19 疫苗接种计划早期阶段,英国接种中心收到的临床咨询的性质。四个中心位于急症医院,一个中心位于指定的公共地点。数据在 2021 年 1 月至 2 月连续八周收集。医院中心共接种了 28995 剂辉瑞-生物科技疫苗,收到 806 次咨询(每接种 36 剂 1 次咨询,2.7%)。公共中心接种了 29167 剂阿斯利康疫苗,收到 439 次咨询(每接种 66 剂 1 次咨询,1.5%)。合并咨询率为 2.1%。最常见的咨询是与过敏(44%)、与其他药物的兼容性(22%)和免疫抑制(16%)有关。这些都是经常变化的临床指导主题。实施新疗法的公共卫生计划应确保提供足够的咨询解答能力。